Thyroid cancer incidence in the United States rose by about 3% per year from 2011 to 2016. More than 80% of cases are detected after thyroid nodules are found incidentally, not because of classic symptoms. Radiation exposure increases risk by 7 to 10 times, and over 85% of tumors are differentiated thyroid cancers.
Key Takeaways
- Thyroid cancer incidence increased by about 3% per year in the US from 2011 to 2016 (SEER trend reported by NCI)
- More than 80% of thyroid cancer cases are diagnosed after incidental detection of thyroid nodules (incidental diagnoses dominate in population-level data)
- In the United States, the median time from abnormal ultrasound to diagnosis of thyroid cancer is reported as ~30 days in clinical workflow studies (varies by system)
- Thyroid cancer is 7–10 times more likely in people who have undergone prior radiation exposure to the head and neck than in the general population
- Over 85% of thyroid cancers are differentiated thyroid cancers (papillary and follicular)
- Anaplastic thyroid cancer accounts for about 1% of thyroid cancers
- Global thyroid cancer burden is estimated at about 43,800 deaths in 2020 (GLOBOCAN 2020)
- US healthcare expenditures attributable to thyroid cancer are in the billions of dollars annually in national cost analyses (SEER-Medicare/claims-based estimates summarized in peer-reviewed work)
- In an analysis of US patients, total costs of thyroid cancer increased substantially after diagnosis (mean costs over follow-up reported in claims study)
US thyroid cancer incidence rose about 3 percent yearly, and most cases are differentiated.
Related reading
01 · Category
Screening & Care Pathways8 stats
01
Thyroid cancer incidence increased by about 3% per year in the US from 2011 to 2016 (SEER trend reported by NCI)
02
More than 80% of thyroid cancer cases are diagnosed after incidental detection of thyroid nodules (incidental diagnoses dominate in population-level data)
03
In the United States, the median time from abnormal ultrasound to diagnosis of thyroid cancer is reported as ~30 days in clinical workflow studies (varies by system)
04
Approximately 50–60% of patients with low-risk papillary microcarcinoma on active surveillance do not require surgery during follow-up (proportion remaining on surveillance varies by study)
05
In differentiated thyroid cancer, radioactive iodine (RAI) is used in selected patients; guidelines commonly consider RAI for intermediate- and high-risk disease (risk-stratified use)
06
Fine-needle aspiration (FNA) is recommended for thyroid nodules based on ultrasound pattern and size thresholds (FNA criteria are explicitly specified in the ATA guideline document)
07
The Bethesda System uses 6 diagnostic categories for thyroid cytology, defining different implied malignancy risks and management pathways
08
Thyroid cancer is among cancers with widespread use of Tg (thyroglobulin) and neck ultrasound for surveillance in differentiated disease (monitoring framework reported in guidelines)
Interpretation
Screening & Care Pathways Interpretation
From 2011 to 2016, thyroid cancer incidence rose by about 3% per year in the US, and in population-level care pathways this appears to be driven largely by incidental detection of thyroid nodules where rapid ultrasound to diagnosis takes roughly 30 days and many low-risk microcarcinoma patients stay on active surveillance without surgery.
02 · Category
Risk Factors & Biology8 stats
01
Thyroid cancer is 7–10 times more likely in people who have undergone prior radiation exposure to the head and neck than in the general population
02
Over 85% of thyroid cancers are differentiated thyroid cancers (papillary and follicular)
03
Anaplastic thyroid cancer accounts for about 1% of thyroid cancers
04
Thyroid cancers are about 3–4 times more common in women than in men for differentiated histologies (papillary/follicular)
05
PTC is characterized by BRAF V600E and RET/PTC rearrangements; BRAF V600E is present in ~45% of papillary thyroid cancers (meta-analysis estimate varies by cohort)
06
RET mutations/rearrangements are present in a substantial fraction of papillary thyroid cancers; RET/PTC rearrangements occur in about 10–20% (cohort estimates vary)
07
About 30% of differentiated thyroid cancers harbor actionable alterations such as BRAF V600E or RET fusion (molecular profiling aggregates)
08
In patients with differentiated thyroid cancer treated with radioactive iodine, about 10–15% develop radioiodine-refractory disease
Interpretation
Risk Factors & Biology Interpretation
From a Risk Factors and Biology perspective, thyroid cancer biology is dominated by differentiated tumors with actionable drivers and clear exposure effects, since over 85% are differentiated and BRAF V600E or RET fusions show up in roughly 30% overall, while prior head and neck radiation raises risk by about 7 to 10 times.
More related reading
03 · Category
Market, Costs & Drugs5 stats
01
Global thyroid cancer burden is estimated at about 43,800 deaths in 2020 (GLOBOCAN 2020)
02
US healthcare expenditures attributable to thyroid cancer are in the billions of dollars annually in national cost analyses (SEER-Medicare/claims-based estimates summarized in peer-reviewed work)
03
In an analysis of US patients, total costs of thyroid cancer increased substantially after diagnosis (mean costs over follow-up reported in claims study)
04
In radioiodine-treated differentiated thyroid cancer, annual follow-up costs vary; published estimates for monitoring (ultrasound, TSH, Tg testing) show multi-hundred-dollar per-year ranges
05
Levemir? (N/A)
Interpretation
Market, Costs & Drugs Interpretation
With an estimated 43,800 thyroid cancer deaths globally in 2020 and US spending reaching billions each year, the Market, Costs & Drugs angle is clear that long term monitoring and treatment driven expenses add up substantially after diagnosis, with radioiodine follow up costs often running into the multi hundred dollar per year range.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Thyroid Cancer Statistics. Gitnux. https://gitnux.org/thyroid-cancer-statistics
MLA
Stefan Wendt. "Thyroid Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/thyroid-cancer-statistics.
Chicago
Stefan Wendt. 2026. "Thyroid Cancer Statistics." Gitnux. https://gitnux.org/thyroid-cancer-statistics.
Sources & references
21 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)